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Abstract
The chronic high-level alcohol consumption seen in alcoholism leads to dramatic effects on the
hippocampus, including decreased white matter, loss of oligodendrocytes and other glial cells, and
inhibition of neurogenesis. Examining gene expression in post mortem hippocampal tissue from
20 alcoholics and 19 controls allowed us to detect differentially expressed genes that may play a
role in the risk for alcoholism or whose expression is modified by chronic consumption of alcohol.
We identified 639 named genes whose expression significantly differed between alcoholics and
controls at a False Discovery Rate (FDR) ≤ 0.20; 52% of these genes differed by at least 1.2-fold.
Differentially expressed genes included the glucocorticoid receptor and the related gene FK506
binding protein 5 (FKBP5), UDP glycosyltransferase 8 (UGT8), urea transporter (SLC14A1), zinc
transporter (SLC39A10), Interleukin 1 receptor type 1 (IL1R1), thioredoxin interacting protein
(TXNIP), and many metallothioneins. Pathways related to inflammation, hypoxia, and stress
showed activation, and pathways that play roles in neurogenesis and myelination showed
decreases. The cortisol pathway dysregulation and increased inflammation identified here are seen
in other stress-related conditions such as depression and post-traumatic stress disorder and most
likely play a role in addiction. Many of the detrimental effects on the hippocampus appear to be
mediated through NF-κB signaling. Twenty-four of the differentially regulated genes were
previously identified by genome-wide association studies of alcohol use disorders; this raises the
potential interest of genes not normally associated with alcoholism, such as suppression of
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tumorigenicity 18 (ST18), BCL2-associated athanogene 3 (BAG3), and von Willebrand factor
(VWF).
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Introduction
Alcohol dependence (alcoholism) is a complex disorder with a 40–60% genetic contribution
to risk (Edenberg & Foroud, 2006; Heath et al., 1997; McGue, 1999). Although several
genes in which variants affect the risk for alcohol dependence have been identified
(Rietschel & Treutlein, 2012), their overall effect accounts for only a small portion of the
vulnerability to alcohol dependence. Many studies are underpowered, and determining
which modest association results are true positives can be difficult. Studies of gene
expression in the human brain can reveal differences between alcoholics and controls that
might be either risk factors or sequelae of excessive drinking; in either case, this increases
the likelihood that such genes are relevant to the disease.
Prior studies have compared gene expression between alcoholics and controls using human
post mortem brains (Flatscher-Bader et al., 2010; Flatscher-Bader et al., 2005; Iwamoto et
al., 2004; Kryger & Wilce, 2010; Lewohl et al., 2000; Liu et al., 2007; Liu et al., 2006;
Mayfield et al., 2002; Sokolov et al., 2003; Zhou et al., 2011b). Others have examined brain
regions from animal models (Edenberg et al., 2005; Kerns et al., 2005; Kimpel et al., 2007;
McBride et al., 2010; Mulligan et al., 2008; Mulligan et al., 2006; Saito et al., 2004;
Tabakoff et al., 2008; Wolen et al., 2012; Worst et al., 2005). The human studies have
examined superior frontal cortex (Lewohl et al., 2000; Liu et al., 2007; Liu et al., 2006),
frontal cortex (Liu et al., 2007), prefrontal cortex (Flatscher-Bader et al., 2005; Iwamoto et
al., 2004), temporal cortex (Sokolov et al., 2003), nucleus accumbens and ventral tegmental
area (Flatscher-Bader et al., 2010; Flatscher-Bader et al., 2005), basolateral amygdala
(Kryger & Wilce, 2010), and hippocampus (Zhou et al., 2011b). These studies have found
down-regulation of myelin-related genes (Liu et al., 2006; Mayfield et al., 2002) and
mitochondrial dysfunction (Liu et al., 2007; Sokolov et al., 2003), and dysregulation of
genes involved in ubiquitination (Liu et al., 2006; Sokolov et al., 2003) and apoptosis and
cell survival (Liu et al., 2004; Liu et al., 2007; Liu et al., 2006).
The hippocampus is a key region related to learning, for which neurogenesis is required
(Winocur et al., 2006). Chronic, excessive consumption of alcohol leads to dramatic effects
on the hippocampus. Hippocampal size is decreased with chronic drinking (Agartz et al.,
1999; Laakso et al., 2000), and abstinence leads to a recovery of this volume loss (Crews &
Nixon, 2009). The decrease in hippocampal size is due to a combination of
neurodegeneration and decreased neurogenesis (Crews & Nixon, 2009; Morris et al., 2010;
Richardson et al., 2009). While neurodegeneration is noted in alcoholism, post mortem
studies of the hippocampus have found glial cell loss but no neuronal loss. A post mortem
study of the hippocampus found a loss of white matter, including oligodendrocytes, but with
no significant loss of neurons (Harding et al., 1997). Alcoholics who had been abstinent
before death did not show a significant loss of white matter, implying that recovery from
this loss is possible (Harding et al., 1997). A second post mortem examination of the
hippocampus showed a 37% loss of glial cells (astrocytes, oligodendrocytes, and to a lesser
extent microglia) in alcoholics (Korbo, 1999). Part of the neurodegeneration in brain is
related to ethanol-induced inflammation through the Toll-like receptors and induction of the
NF-κB pathway (Alfonso-Loeches et al., 2012; Crews & Nixon, 2009; Qin & Crews, 2012).
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Neuroinflammation may also play a part in the addiction process because alcohol and stress
induce innate immune genes via the NF-κB pathway that lead to changes in behavior that
mimic addiction (Blednov et al., 2011; Blednov et al., 2012; Crews et al., 2011; Mayfield et
al., 2013). Inflammation has been seen to block neurogenesis through the NF-κB pathway in
depression (Koo et al., 2010), and neurogenesis can be restored by blocking inflammation
(Monje et al., 2003).
To obtain a global picture of changes in gene expression in the hippocampi of alcoholics, we
conducted a microarray study of post mortem hippocampi from 20 alcoholics and 19
controls. We report the differences in gene expression between alcoholics and controls and
the pathways affected. We compare our results with genes identified in other human brain
expression studies and in genome-wide association studies (GWAS) for alcohol dependence
or phenotypes associated with alcohol use disorders to look for genes in common and the
pathways they delineate.
Materials and Methods
Hippocampal tissue from 20 alcoholics and 19 controls, all of European background (6
females in each group), was obtained from the New South Wales Tissue Resource Centre at
the University of Sydney, Australia (Sheedy et al., 2008). Supplemental Table S1 describes
the samples used. Total RNA was extracted using TRIzol® Reagent (Invitrogen; Carlsbad,
CA) following a modified protocol with twice as much TRIzol® per gram of tissue
(Edenberg et al., 2005). RNA was further purified using the Qiagen RNeasy mini-kit
(Qiagen; Valencia, CA). Quality of the RNA, determined using the Agilent Bioanalyzer
(Agilent; Santa Clara, CA), did not significantly differ between the 2 groups (mean RIN 6.8,
SD 1).
RNA was labeled and hybridized to Affymetrix Gene 1.0 ST arrays, following the standard
WT protocol (GeneChip® Whole Transcript [WT] Sense Target Labeling Assay, rev. 5,
www.affymetrix.com). Samples were processed in 2 groups, balanced by phenotype and
sex. Arrays were scanned and data were imported into Partek Genomics Suite version 6.2
(Partek, Inc.; St. Louis, MO).
Robust Multichip Average signals (RMA) (Irizarry et al., 2003) were generated for the core
probe sets using the RMA background correction. Quantile normalization and
summarization was done by Median Polish analysis using the Partek Genomics Suite.
Summarized signals for each probe set were log2 transformed. These data are deposited in
the NCBI Gene Expression Omnibus under series number GSE44456. The log2 transformed
signals were used for principal components analysis, hierarchical clustering, and signal
histograms to determine if there were any outlier arrays; none were found. We have
previously shown that removing probe sets not reliably detected above background in any
experimental condition improves analysis by reducing the multiple testing burden
(McClintick & Edenberg, 2006). The signal histogram (not shown) indicated that probe sets
with log2 values < 4 were at background level. Therefore, probe sets with mean log2 values
< 4.0 in both alcoholics and controls were removed. The remaining probe sets were analyzed
using a 3-way ANOVA with the factors of phenotype (control/alcoholic), sex (male/female),
and processing batch (for potential technical variations). Interaction between sex and
phenotype was not significant after correcting for multiple testing (Storey & Tibshirani,
2003) and was removed from the analysis. Fold changes were calculated using the
untransformed RMA signals. False discovery rates (FDR) were calculated using q-value
(Storey & Tibshirani, 2003).
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We collected lists of differentially expressed genes from 10 other gene expression studies of
post mortem brain tissue comparing alcoholics to controls (Flatscher-Bader et al., 2010;
Flatscher-Bader et al., 2005; Iwamoto et al., 2004; Kryger & Wilce, 2010; Lewohl et al.,
2000; Liu et al., 2007; Liu et al., 2006; Mayfield et al., 2002; Sokolov et al., 2003; Zhou et
al., 2011b). Similarly, we assembled lists of genes identified in 12 recent GWAS studies of
risk for alcoholism or related traits (Bierut et al., 2010; Edenberg et al., 2010; Foroud et al.,
2007; Hack et al., 2011; Johnson et al., 2011; Kendler et al., 2011; Lind et al., 2010;
Treutlein et al., 2009; Wang et al., 2012; Xuei et al., 2006; Zlojutro et al., 2011; Zuo et al.,
2012). We annotated the list of differentially expressed genes from our study (Supplemental
Table S2) to show these overlaps. We also created a list of genes identified by 2 or more
studies (including the present one) in Supplemental Table S4; these will be referred to as
“multiply-identified genes” in the rest of the text.
To identify transcripts enriched in different cell types we used 3 files from Cahoy et al.
(2008): astrocytes (Cahoy Supplemental Table S4), oligodendrocytes (Cahoy Supplemental
Table S5), and neurons (Cahoy Supplemental Table S6). These were matched by the official
gene symbol (HUGO Gene Nomenclature Committee) to our data set.
Ingenuity Pathway Analysis (IPA, www.Ingenuity.com) was performed using probe sets
with an FDR ≤ 0.20 to examine Canonical Pathways. For all of our analyses the Ingenuity
knowledge base was used as the reference set to insure all analyses used similar parameters.
We analyzed the list of probe sets identified at FDR ≤ 0.20 from our study, the list of
multiply identified genes described above, and the cell-type enriched sets of genes described
above. We also carried out an IPA Upstream Regulator report to identify transcription
factors, cytokines, and chemicals, etc. that are predicted to be activated or inactivated based
on the direction of change in their downstream targets; a positive Z-score indicates likely
activation and a negative Z-score indicates likely inactivation in alcoholics relative to the
controls.
Quantitative Real-Time PCR (qRT-PCR) was used to confirm differences in 4 genes:
FKBP5, GRM3, NR3C1, and NR4A2. Primers were selected from Life Technologies™
(Carlsbad, CA) catalog of Taqman® Gene Expression Assays (http://
bioinfo.appliedbiosystems.com/genome-database/gene-expression.html). One µg of total
RNA from each sample was used for reverse transcription using the High Capacity cDNA
Reverse Transcription Kit (Life Technologies™, Carlsbad, CA). Each gene of interest was
measured in duplicate using TaqMan® Fast Advanced Master Mix (Life Technologies).
Primers for POL2RA (Taqman® primer: Hs00172187_m1) were included in each well as a
control. The CT of the POL2RA run in the same well was subtracted from the CT of the
target gene to yield the Delta CT (relative expression). The Delta CT from 2 replicates for
each sample was used in a 3-way ANOVA using phenotype, sex, and sample ID as factors.
Results
We analyzed RNA extracted from the hippocampi of 20 alcoholics and 19 controls (6
females in each group) using Affymetrix Gene 1.0 ST microarrays. Supplemental Table S1
describes the samples. Subject age and RNA integrity (RIN) did not significantly differ
between alcoholics and controls (all p > 0.4). The single factor that most affects microarray
measurement of gene expression from post mortem brain tissue is the pH (Atz et al., 2007);
pH (mean 6.5, SD 0.3) did not significantly differ between alcoholics and controls. A total
of 22,987 probe sets (80% of the core probe sets on the Affymetrix Gene 1.0 ST array) were
expressed (detected above background) in at least 1 of the 2 groups (alcoholics or controls).
A 3-way ANOVA using factors for phenotype (alcoholic/control), sex, and microarray-
processing batch detected 743 probe sets that significantly differed between alcoholics and
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controls at a False Discovery Rate (FDR) ≤ 0.20. This represented 639 named genes (46 of
which were measured twice) plus 58 unnamed probe sets (Supplemental Table S2). Among
the significant probe sets, 50% (52% of the named genes) showed absolute fold changes ≥
1.2 (Figure 1). Slightly over half the changes (53%) reflected lower expression in the
alcoholics.
Large fold changes were found among genes associated with inflammatory and immune
response (GO:0006954 and GO:0006955), particularly interleukin receptors (Table 1A).
Twenty-one genes involved in hypoxia (GO:0001666) were differentially expressed, with
two-thirds of them showing higher expression in the brains of alcoholics (Table 1B). The
expression of most genes in the glucocorticoid pathway, including the glucocorticoid
receptor (NR3C1) and 2 FK506 binding proteins (FKBP4, FKBP5), differed significantly
between alcoholics and controls. NR3C1 expression was 30% lower in alcoholics, whereas
FKBP5, which functions as a negative regulator of the pathway, was increased over 2-fold
(Table 1C). Genes related to myelination and oligodendrocytes demonstrated decreased
expression in the alcoholic hippocampi (Table 1D). Fourteen of 16 significantly changed
genes in this group were expressed at lower levels in alcoholics, averaging 74%, whereas
only 2 were at higher levels. Eight metallothioneins (MT) with an FDR ≤ 20% were
expressed at higher levels in the hippocampus of alcoholics (mean 1.44-fold), and 9 more
(20% < FDR ≤ 40%) were also expressed at higher levels in alcoholics (mean 1.2-fold;
Table 1E).
Ingenuity Pathways Analysis (IPA) of genes with FDR ≤ 0.20 revealed many canonical
pathways that differed between alcoholics and controls (Table 2). Signaling pathways
predominated, along with stress or immune responses. Acute phase response signaling, IL-6
signaling, IL-8 signaling, IL-10 signaling, LPS/IL-1 mediated inhibition of RXR function,
mTOR signaling, hypoxia signaling, p38 MapK signaling, EIF2 signaling (eukaryotic
translation initiation factor 2), and glucocorticoid signaling were up. GADD45 (growth
arrest and DNA-damage-inducible) signaling, p38 signaling, and Her2 signaling, were
mixed or down. Many of the pathways shared key genes. ATM (ataxia telangiectasia
mutated; down 20%) is in 39 of the 60 pathways and AKT1 (v-akt murine thymoma viral
oncogene homolog 1; increased 8%) is in 32 of the pathways. TRAF6, PRKD1, MAP2K3,
RHOB and RHOC, CREB1, CCND, and the guanine binding proteins GNAI1, GNB2, and
GNG5 were each in at least 12 of the pathways.
To see whether the alcoholics differed in expression of genes enriched in particular cell
types, we examined the sets of genes whose expression is known to be enriched in
astrocytes, oligodendrocytes, or neurons (Cahoy et al., 2008), noted in Supplemental Table
S2. The vast majority of these cell-enriched genes were not differentially expressed: about
95% have FDR > 0.20. However, for those genes that were differentially expressed, the
fraction up and down was skewed compared to the overall results. Eighty-three percent of
the differentially expressed transcripts enriched in oligodendrocytes were expressed at lower
levels in alcoholics (p = 3.9 × 10−9), as were 83% of the differentially expressed transcripts
in neurons (p = 2.1 × 10−4), whereas only 53% of the total probe sets were down. The
differentially expressed genes expressed in astrocytes demonstrated the opposite trend, with
61% at higher levels in alcoholics (p = 0.003), including hypoxia response genes.
Analyzing upstream regulators can clarify the pathway findings by looking for
commonalities in their regulation, i.e. it may be possible to identify sets of differentially
expressed genes that are downstream targets of specific transcription factors, cytokines,
signaling cascades, and endogenous and exogenous chemicals. Both the glucocorticoid and
aldosterone pathways were significantly altered in alcoholic brains, and the upstream
effectors analysis indicated that their receptors, NR3C1 and NR3C2, are in an activated state
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(Supplemental Table S3). Other genes identified as activated include many regulators
related to immune function (including cytokines IL1B, IL10, IL11, IL15, IL17A, and
EDN1), other regulators, including hypoxia-related gene HIF1A and Endothelial PAS
domain-containing protein 1 (EPAS1), and 2 genes that are general indicators of stress,
TP53 and TGFB1. The expression of downstream targets for the Wnt/β catenin pathway and
the ERBB4 pathways involved in neurogenesis (Lazarov & Marr, 2010), including TCF4
and cyclin D1, provide evidence that both of these pathways were less active in the
alcoholics (Supplemental Table S3).
Bioinformatic analysis found 386 genes that were identified in 2 or more studies (GWAS or
gene expression, including the present study), which we refer to as multiply identified genes
(listed in Supplemental Table S4). One hundred seven of these genes were identified by our
study and at least one other (noted in Supplemental Tables S2 & Supplemental Tables S4).
Twenty-four of these 107 were identified by at least one of the GWAS (Supplemental Table
S2). The 386 multiply identified genes (Supplemental Table S4) were used for Ingenuity
analysis, and 81 pathways were significantly altered (p < 0.05; Supplemental Table S5).
There were 21 pathways in common between the multiply identified genes and our dataset
(section A of Table 2 and of Supplemental Table 5).
We chose 4 genes to test by qRT-PCR, based upon their roles in pathways that are affected.
NR3C1 is the glucocorticoid receptor gene, the key transcription factor in the glucocorticoid
pathway. FKBP5 (FK506 binding protein 5) is an immunophilin gene important in that
pathway that also interacts with 90 kDa heat shock protein and sequesters NR3C1 in the
cytosol, increasing glucocorticoid resistance. NR4A2 is a transcription factor in the steroid-
thyroid hormone-retinoid receptor superfamily, mutations in which have been related to
dopaminergic dysfunction. NR4A2 has been shown to repress inflammatory genes activated
by NF-κB (Saijo et al., 2009) in microglia. GRM3 (glutamate receptor, metabotropic 3) was
chosen because L-glutamate is the major excitatory neurotransmitter in the central nervous
system, and affects most aspects of brain function. All 4 genes showed similar fold-changes
in qRT-PCR as they did in the microarrays (Table 3).
Discussion
This study presents a global picture of differences between alcoholics and controls in gene
expression in the post mortem hippocampus. A major theme that emerges from the data is
that the hippocampus in alcoholics shows dramatic signs of stress. Genes and pathways
(Table 2) involved in stress responses are mostly increased in alcoholics. Metallothioneins, a
large number of which are increased in the hippocampus (Table 1E), are increased in many
stress conditions (Aschner & West, 2005). EIF2 signaling, which is increased, functions to
resolve endoplasmic reticulum (ER) stress; if ER stress cannot be resolved, apoptosis can
result (Lerner et al., 2012). TXNIP (1.7-fold higher in alcoholics) can be transcriptionally
induced by TGFβ1 and glucocorticoids (Chen et al., 2010; Han et al., 2003), and can link
oxidative stress to inflammation via the NLRP3 inflammasome (NLR family, pyrin domain
containing 3) (Zhou et al., 2010), an upstream activator of NF-κB signaling that plays a role
in the regulation of inflammation, the immune response, and apoptosis.
Signs of hypoxia are present, as evidenced by the increases in Angiopoietin-like 4, EPAS1
(endothelial PAS domain protein 1, also known as HIF2α), HIF3α, and HIF1α (15%
increase, FDR 0.26) shown in Supplemental Table S2. Analysis of upstream regulators
(Supplemental Table S3) reinforces this, since the pattern of expression of the genes
regulated by EPAS1 and HIF1α also indicates that they are activated.
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There is also evidence of involvement of the hypothalamus-pituitary-adrenal (HPA) axis,
specifically the cortisol pathway (Table 1C), and particularly in astrocytes: 37% of the
astrocyte-enriched genes that showed increased expression are downstream of the
glucocorticoid signaling, and others are downstream of either IL1β or TGFβ1. Pathway and
upstream analysis (Table 2, Supplemental Table S3) indicates that the glucocorticoid
receptor is activated although its transcript level (NR3C1) is decreased. Cortisol-releasing-
hormone (CRH) increases as a result of stress, ethanol abuse, chronic drinking, and the early
stage of withdrawal (Armario, 2010; Gianoulakis et al., 2003; Roy et al., 2002), which
should activate the glucocorticoid receptor. The HPA and CRH are also activated by alcohol
consumption (Clarke & Schumann, 2009), increasing the amount of adrenocorticotropic
hormone (ACTH) produced, which in turn stimulates the release of glucocorticoids
(Mesotten et al., 2008). Glucocorticoids down-regulate the further release of CRH through a
negative feedback loop to the hypothalamus, but increase the production of CRH outside the
hypothalamus, e.g. in the central amygdala (Pastor et al., 2008). Dysregulation of the HPA
axis is a known problem in alcoholism and other addictions (Armario, 2010; Koob & Kreek,
2007; Sorocco et al., 2006) as well as in at-risk individuals (Sorocco et al., 2006). The
increased levels of CRH may lead to increased alcohol consumption as the brain tries to
adapt to its increasingly dysregulated state (Koob & Le Moal, 2005). Increased CRH levels
also lead to increased sensitivity of stress-induced alcohol consumption (Ciccocioppo et al.,
2009; Clarke et al., 2009). Glucocorticoids mediate the development of sensitization to
drugs such as ethanol (Roberts et al., 1995) in a feed-forward fashion.
FKBP4 and FKBP5 (over 2-fold higher) and NR3C1 itself are downstream targets of
glucocorticoid signaling. FKBP5 functions as a negative regulator of the pathway by
lowering the cortisol affinity of the glucocorticoid receptor and keeping it in the cytoplasm,
which increases cortisol resistance and short-circuits the glucocorticoid feedback circuit
(Binder, 2009; Binder et al., 2008). Mice with chronic exposure to corticosterone (the rodent
equivalent of cortisol) develop anxiety and have decreased expression of Nr3c1 and Hsp90
and increased expression of FKBP5 in many tissues (Lee et al., 2010). Increased FKBP5
expression due to known polymorphisms leads to increased risk of affective and anxiety
disorders (Binder et al., 2008) and bipolar disorder (Willour et al., 2009).
Our data show decreased myelination (Table 1D) in the hippocampus. Decreased
hippocampal volume (Agartz et al., 1999; Laakso et al., 2000; Tyan et al., 2012) and
decreases in hippocampal neurogenesis have been observed in alcoholism (Crews & Nixon,
2009; Morris et al., 2010; Richardson et al., 2009). Pathways (WNT/β catenin, reelin
signaling in neurons, and ERBB4) and genes (APP, PSEN1, ADAM10, ERBB2, and reelin)
that play a role in neurogenesis (Lazarov & Marr, 2010) have decreased activity or
expression in the hippocampi of the alcoholics. Both inflammation (Monje et al., 2003) and
stress with increased cortisol production (Schoenfeld & Gould, 2012) can inhibit
neurogenesis. Chronic cortisol decreases neurogenesis and treatment with the glucocorticoid
antagonist mifepristone reverses this reduction (Mayer et al., 2006).
Are these stresses and dysfunctional changes related? Most of these stresses can be linked to
NF-κB (Figure 2), which is connected to 25 of the differentially expressed genes in this
dataset, including genes related to hypoxia, inflammation, neurogenesis, and myelin.
Variations within NFKB1, a subunit of NF-κB, have been associated with alcoholism
(Edenberg et al., 2008). One can conceptualize the inter-relationships as in Figure 3. Ethanol
activates inflammation via the TLR4 pathway and NF-κB. Increased inflammation, via the
toll-like receptor 4 (TLR4), can play a role in the loss of white matter seen in alcoholics
(Alfonso-Loeches et al., 2012). Wild-type mice chronically treated with ethanol for 5
months had decreased expression of several myelin-related genes in multiple brain regions,
and also a reduced number of oligodendrocytes, but Tlr4 knockout mice similarly treated did
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not show decreased expression of the myelin genes. The ER stress we have found, if
unresolved, can also increase inflammation via TXNIP (strongly increased) and NF-κB.
One goal of examining gene regulation in the brain is to inform the analyses of genes that
may influence risk for alcoholism. Toward that end, we compiled data from 10 previously
published gene expression studies (Flatscher-Bader et al., 2010; Flatscher-Bader et al., 2005;
Iwamoto et al., 2004; Kryger & Wilce, 2010; Lewohl et al., 2000; Liu et al., 2007; Liu et al.,
2006; Mayfield et al., 2002; Sokolov et al., 2003; Zhou et al., 2011b), from this study, and
from 12 GWAS for risk of alcoholism or alcoholic traits (Bierut et al., 2010; Edenberg et al.,
2010; Foroud et al., 2007; Hack et al., 2011; Johnson et al., 2011; Kendler et al., 2011; Lind
et al., 2010; Treutlein et al., 2009; Wang et al., 2012; Xuei et al., 2006; Zlojutro et al., 2011;
Zuo et al., 2012). There were 386 genes identified by at least 2 of these collected studies
(Supplemental Table S4). Five genes were identified in 4 studies, and are thus strong
candidates for further study: selenoprotein P (SEPP1), heterochromatin protein 1 binding
protein 3 (HP1BP3), transferrin (TF), EGF-like repeats and discoidin I-like domains 3
(EDIL3), and contactin associated proteinlike 2 (CNTNAP2). SEPP1 binds selenium and
has antioxidant activity and is down-regulated by both inflammatory cytokines like IL1β
(Dreher et al., 1997) and glucocorticoids (Rock & Moos, 2009); it is decreased in the
hippocampi of alcoholics (Supplementary Table S2). Transferrin is an iron transporter and is
also a negative acute phase response protein; it is also decreased. HP1BP3 has been
identified as a biomarker for postpartum depression (Guintivano et al., 2013). EDIL3 can
stimulate cerebral angiogenesis (Fan et al., 2008) and was down-regulated in mouse
embryos exposed to ethanol (Zhou et al., 2011a). CNTNAP2 is an extremely large protein in
the neurexin family, polymorphisms in which were recently found to be associated with
depression and schizophrenia in a Han Chinese population (Ji et al., 2013). Several
pathways identified using this list of genes overlap with the pathways identified by our study
(Supplemental Table S5, Section A) which include stress-related pathways EIF2 and mTOR
signaling. IPA also identified NF-κB as significantly altered for this group of multiply
identified genes.
Twenty-four of the genes identified by our study were previously identified by GWAS
(Supplemental Table S2, GWAS column). This list includes several genes with large fold
changes, such as SLC39A10 (a zinc transporter), suppression of tumorigenicity 18 (ST18),
protein tyrosine phosphatase receptor type D (PTPRD), BCL2-associated athanogene 3
(BAG3), and von Willebrand factor (VWF). Although these genes might not be thought of
as related to alcoholism, their differential expression in alcoholic brains, together with their
genetic connection, suggests they might be. The IPA analysis of the 107 genes in our study
that were identified in other studies indicated that 38 of these genes are related to cell death,
including ST18 and BAG3.
This study demonstrates many differences in gene expression between the hippocampi of
alcoholics and controls, and highlights interrelated insults to the hippocampus: stress,
hypoxia, inflammation, and excess cortisol (Figures 2, 3). These may play roles in the
demyelination, loss of glial cells, and decreased neurogenesis seen with chronic alcohol
abuse. NF-κB appears to be a key player in these processes (Figure 3). Some of these
differences in gene expression may be due to genetic variations that precede the addiction
process and may play an active role in the addiction process. Others may be the result of
years of excessive alcohol consumption, and still others may be altered due to the interaction
of genetic variation with excessive alcohol consumption. A post mortem study such as this
cannot distinguish among these possibilities. The modifications seen here in gene expression
in these pathways could be part of the allostatic change suggested by Koob & Kreek (2007).
In the hippocampus, resetting the cortisol pathway may be one way to break this chain of
events. Decreased neurogenesis and increased inflammation are also seen in major
McClintick et al. Page 8
Alcohol. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
depressive illness (Koo et al., 2010), but antidepressant treatment has had mixed results in
the treatment of alcoholism per se (Kranzler et al., 2012). Animal and human post mortem
research indicate the innate immune function induced by TLRs and NF-κB signaling creates
negative affect and stress, which with repeated cycles of ethanol abuse leads to addiction
(Crews et al., 2011). This study demonstrates that this increase in the innate immune system
and NF-κB signaling is still present after years of chronic drinking. With multiple stressors
increasing NF-κB signaling, it may take a multi-pronged approach to normalize the brain of
chronic drinkers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Distribution of fold changes for the 743 transcripts significant at FDR ≤ 0.20
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Figure 2. Ingenuity Pathway Analysis network with NF-κB as central hub
Red: genes with increased expression; green: genes with decreased expression; gray: gene in
dataset but was not significantly changed; white: not in the data set used for analysis.
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Figure 3. Key pathways affected by ethanol
Ethanol intake increases cortisol and activates NF-κB via Toll-like receptor 4 (TLR4). NF-
κB activation increases innate immune activity. Hippocampal neurogenesis is inhibited via
NFκB. NR4A2 represses NF-κB transactivation of other genes. When stress cannot be
resolved by the eIF2 pathway, transcription of TXNIP is increased which also increases NF-
κB transactivation. Red and Green vertical arrows indicate pathways, genes, or signaling
molecules that have increased/decreased expression or activity in the hippocampus of
alcoholics.
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Table 1
Functional categories of selected genes that significantly differ between alcoholics and controls (FDR ≤ 0.20)
A. Inflammatory / immune response GO (0006954 & 0006955)
Gene symbol Gene title Fold p value FDR
ENPP2 ectonucleotide
pyrophosphatase/phosphodiesterase 2
−1.55 1.1E-02 0.21
TAC1 tachykinin, precursor 1 −1.53 2.9E-02 0.27
TNFSF10 tumor necrosis factor (ligand)
superfamily, member 10
−1.37 1.5E-02 0.23
LIPA lipase A, lysosomal acid, cholesterol
esterase
−1.34 1.4E-03 0.13
HDAC9 histone deacetylase 9 −1.31 7.8E-03 0.19
PXK PX domain containing serine/threonine
kinase
−1.31 5.8E-03 0.18
IKBKAP inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase complex-associated protein
−1.23 3.8E-04 0.08
SEMA4D sema domain, immunoglobulin domain
(Ig), transmembrane domain (TM) and
short cytoplasmic domain,
−1.22 1.2E-02 0.21
KLRG1 killer cell lectin-like receptor subfamily
G, member 1
−1.21 5.6E-04 0.10
BLNK B-cell linker −1.20 3.2E-02 0.28
OAS1 2’,5’-oligoadenylate synthetase 1,
40/46kDa
−1.20 2.6E-03 0.15
PRKRA protein kinase, interferon-inducible
double stranded RNA dependent
activator
−1.20 2.7E-02 0.27
PLA2G4C phospholipase A2, group IVC
(cytosolic, calcium-independent)
−1.18 3.6E-02 0.29
IGKC immunoglobulin kappa constant −1.13 1.6E-02 0.23
TRAF6 TNF receptor-associated factor 6 −1.12 4.1E-03 0.16
ITCH itchy E3 ubiquitin protein ligase
homolog (mouse)
−1.11 2.7E-02 0.27
ADORA1 adenosine A1 receptor −1.11 3.4E-03 0.16
AKT1 v-akt murine thymoma viral oncogene
homolog 1
1.08 7.0E-03 0.19
GTPBP1 GTP binding protein 1 1.10 3.1E-03 0.15
KIR2DL3 killer cell immunoglobulin-like receptor,
two domains, long cytoplasmic tail, 3
1.10 2.7E-02 0.27
FCGRT Fc fragment of IgG, receptor,
transporter, alpha
1.12 2.7E-02 0.27
CEBPB CCAAT/enhancer binding protein
(C/EBP), beta
1.13 3.7E-02 0.29
LTB4R leukotriene B4 receptor 1.13 6.5E-03 0.18
FTH1 ferritin, heavy polypeptide 1 1.13 3.0E-02 0.28
SMAD1 SMAD family member 1 1.14 1.5E-02 0.23
MR1 major histocompatibility complex, class
I-related
1.15 3.2E-02 0.28
PROK2 prokineticin 2 1.15 3.5E-02 0.29
ULBP2 UL16 binding protein 2 1.18 2.8E-02 0.27
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A. Inflammatory / immune response GO (0006954 & 0006955)
Gene symbol Gene title Fold p value FDR
S1PR3 sphingosine-1-phosphate receptor 3 1.20 1.4E-02 0.22
TGFBR3 transforming growth factor, beta
receptor III
1.25 1.2E-02 0.21
TNFRSF1A tumor necrosis factor receptor
superfamily, member 1A
1.25 2.6E-03 0.15
KIR2DL3 killer cell immunoglobulin-like receptor,
two domains, long cytoplasmic tail, 3
1.27 3.1E-02 0.28
C1R complement component 1, r
subcomponent
1.27 7.8E-03 0.19
PNP purine nucleoside phosphorylase 1.27 2.9E-03 0.15
TARP TCR gamma alternate reading frame
protein
1.39 3.0E-04 0.08
IFITM2 interferon induced transmembrane
protein 2 (1–8D)
1.46 1.7E-03 0.14
SLC11A1 solute carrier family 11 (proton-coupled
divalent metal ion transporters),
member 1
1.51 2.1E-03 0.14
IL4R interleukin 4 receptor 1.57 2.1E-04 0.08
IFITM3 interferon induced transmembrane
protein 3 (1-8U)
1.60 6.2E-05 0.05
IL1R1 interleukin 1 receptor, type I 1.71 1.7E-05 0.03
CD163 CD163 molecule 1.80 3.7E-03 0.16
S100A8 S100 calcium binding protein A8 1.85 7.8E-03 0.19
IL1RL1 interleukin 1 receptor-like 1 1.87 7.9E-04 0.11
SERPINA3 serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin),
member 3
2.28 4.0E-03 0.16
B. Hypoxia GO (0001666)
Gene symbol Gene title Fold p value FDR
ITGA2 integrin, alpha 2 (CD49B, alpha 2
subunit of VLA-2 receptor)
−1.40 1.5E-02 0.23
PYGM phosphorylase, glycogen, muscle −1.29 2.8E-02 0.27
VLDLR very low density lipoprotein receptor −1.28 3.7E-03 0.16
PRKCQ protein kinase C, theta −1.21 2.8E-02 0.27
HSP90B1 heat shock protein 90kDa beta (Grp94),
member 1
−1.17 1.5E-02 0.23
ADAM17 ADAM metallopeptidase domain 17 −1.14 3.0E-02 0.28
BIRC2 baculoviral IAP repeat-containing 2 −1.13 1.7E-02 0.24
EGLN2 egl nine homolog 2 (C. elegans) 1.10 8.0E-03 0.19
PLD2 phospholipase D2 1.11 2.9E-02 0.28
ECE1 endothelin converting enzyme 1 1.14 3.7E-02 0.29
HIF1A hypoxia inducible factor 1, alpha
subunit (basic helix-loop-helix
transcription factor)
1.15 2.0E-02 0.25
SOD2 superoxide dismutase 2, mitochondrial 1.16 1.7E-02 0.24
SDC2 syndecan 2 1.18 2.5E-02 0.27
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A. Inflammatory / immune response GO (0006954 & 0006955)
Gene symbol Gene title Fold p value FDR
ADM adrenomedullin 1.25 2.2E-02 0.26
SOCS3 suppressor of cytokine signaling 3 1.31 7.6E-03 0.19
TGFB3 transforming growth factor, beta 3 1.32 3.7E-02 0.29
DDIT4 DNA-damage-inducible transcript 4 1.39 7.9E-03 0.19
HIF3A hypoxia inducible factor 3, alpha
subunit
1.40 1.5E-03 0.13
PDLIM1 PDZ and LIM domain 1 1.42 1.1E-02 0.21
ANGPTL4 angiopoietin-like 4 1.57 8.6E-05 0.06
EDN1 endothelin 1 1.65 3.3E-04 0.08
C. HPA Axis
Gene symbol Gene title Fold p value FDR
HSPA1A heat shock 70kDa protein 1A −1.47 7.7E-03 1.9E-01
HSP90AA1 heat shock protein 90kDa alpha
(cytosolic), class A member 1
−1.37 3.7E-04 8.5E-02
HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) −1.29 1.9E-03 1.4E-01
NR3C1 nuclear receptor subfamily 3, group C,
member 1 (glucocorticoid receptor)
−1.29 1.8E-05 2.7E-02
HSPA8 heat shock 70kDa protein 8 −1.26 7.7E-03 1.9E-01
FKBP4 FK506 binding protein 4, 59kDa −1.16 3.4E-03 1.6E-01
FKBP5 FK506 binding protein 5 2.21 4.6E-06 2.1E-02
D. Myelination
Gene symbol Gene title Fold p value FDR
UGT8 UDP glycosyltransferase 8 −1.73 1.4E-04 0.07
ENPP2 ectonucleotide
pyrophosphatase/phosphodiesterase 2
−1.55 1.1E-02 0.21
KLK6 kallikrein-related peptidase 6 −1.46 3.0E-03 0.15
MOG myelin oligodendrocyte glycoprotein −1.46 3.6E-03 0.16
TF transferrin −1.44 6.0E-03 0.18
ASPA aspartoacylase −1.28 6.6E-02 0.33
PLP1 proteolipid protein 1 −1.26 1.6E-03 0.14
OMG oligodendrocyte myelin glycoprotein −1.25 3.9E-03 0.16
PLLP plasmolipin −1.23 1.9E-02 0.25
MAG myelin associated glycoprotein −1.23 8.1E-02 0.35
CNP 2’,3’-cyclic nucleotide 3’
phosphodiesterase
−1.20 4.2E-02 0.30
ERBB3 v-erb-b2 erythroblastic leukemia viral
oncogene homolog 3 (avian)
−1.20 4.3E-02 0.31
PMP2 peripheral myelin protein 2 −1.18 5.8E-02 0.33
MYEF2 myelin expression factor 2 −1.09 3.6E-02 0.29
MYT1 myelin transcription factor 1 1.16 2.4E-02 0.26
MPZL2 myelin protein zero-like 2 1.84 1.5E-03 0.14
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A. Inflammatory / immune response GO (0006954 & 0006955)
Gene symbol Gene title Fold p value FDR
E. Metallothioneins
Gene symbol Gene title Fold p value FDR
MT1X metallothionein 1X 1.98 1.8E-05 0.03
MT1M metallothionein 1M 1.50 1.1E-03 0.13
MT1A metallothionein 1A 1.48 2.6E-04 0.08
MT2A metallothionein 2A 1.47 1.1E-03 0.13
MT1G metallothionein 1G 1.38 2.1E-02 0.25
MT1L metallothionein 1L (gene/pseudogene) 1.37 2.0E-03 0.14
MT1JP metallothionein 1J (pseudogene) 1.26 1.6E-02 0.23
MT1P3 metallothionein 1 pseudogene 3 1.25 3.3E-03 0.16
MT1DP metallothionein 1D (pseudogene) 1.24 7.1E-03 0.19
MT1E metallothionein 1E 1.22 5.7E-02 0.33
MT1B metallothionein 1B 1.21 1.1E-02 0.21
MT1P2 metallothionein 1 pseudogene 2 1.21 6.9E-03 0.19
MT1F metallothionein 1F 1.19 1.1E-01 0.37
MT3 metallothionein 3 1.16 6.1E-02 0.33
MT1H metallothionein 1H 1.15 6.4E-02 0.33
MT1IP metallothionein 1I (pseudogene) 1.14 4.6E-02 0.31
MT4 metallothionein 4 1.13 7.4E-02 0.34
Alcohol. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
McClintick et al. Page 22
Table 2
Ingenuity pathway analysis using genes differentially expressed in hippocampi of
alcoholics
Pathways in Section A are common to genes identified in multiple studies. Section B lists pathways identified
only in this study.
Canonical Pathways p value Significant genes in the pathway
A. Pathways common to multiple studies
Acute Phase Response
Signaling
1.1E-04 SOCS3, TCF4, SERPING1, TNFRSF1A
MAP3K1, VWF, SERPINA3, IL1R1, NR3C1
TRAF6, C1R, AKT1, TF, CFB, MAP2K3, OSMR
Aldosterone Signaling in
Epithelial Cells
1.1E-04 HSPA1A/HSPA1B, HSPH1, SLC12A2, DNAJA1
HSPA5, HSPA1L, PLCD1, HSPA8, HSPE1
HSP90AA1, HSPB7, DNAJB6, PLCD4, PRKD1
ATM
Axonal Guidance Signaling 2.1E-02 PXN, PAPPA, C9orf3, GNAI1, DPYSL5, SLIT2
ADAMTS9, TUBA1B, PLCD1, SEMA6D, AKT1
GNB2, ADAM10, RTN4, GNG5, ERBB2
SEMA4B, PLCD4, MYL3, FARP2, PRKD1, ATM
Cell Cycle: G1/S Checkpoint
Regulation
4.9E-02 HDAC9, CCND3, PAK1IP1, CCND1, ATM
CXCR4 Signaling 2.6E-02 PXN, AKT1, RHOB, RHOC, GNB2, GNAI1
GNG5, MYL3, PRKD1, ATM
Cyclins and Cell Cycle
Regulation
4.4E-02 CCNA2, HDAC9, CCNA1, CCND3, CCND1
ATM
EIF2 Signaling 2.8E-05 RPL24, RPS2, RPL23A, RPS17/RPS17L
RPLP0, RPL7, RPL10A, RPL35, RPS3A, AKT1
RPL7A, RPL39, RPL19, RPL12, RPS5, RPL29
ATM, RPSA
Estrogen-mediated S-phase
Entry
4.1E-02 CCNA2, CCNA1, CCND1
Glioma Invasiveness Signaling 3.8E-02 TIMP4, RHOB, TIMP1, RHOC, ATM
HGF Signaling 4.2E-02 PXN, AKT1, MAP3K6, MAP3K1, CCND1
PRKD1, ATM
ILK Signaling 4.0E-02 PXN, CDH1, AKT1, RHOB, TNFRSF1A, RHOC
CREB1, ITGB4, CCND1, MYL3, ATM
Inhibition of Matrix
Metalloproteases
7.9E-03 TIMP4, TIMP1, THBS2, ADAM10, MMP24
mTOR Signaling 3.5E-03 NAPEPLD, DDIT4, RHOC, RPS2, PRR5L
RPS17/RPS17L, PLD1, AKT1, RPS3A, RHOB
RPS5, PRKD1, ATM, RPSA
p70S6K Signaling 4.0E-02 PLCD1, IL4R, AKT1, GNAI1, PLCD4, PLD1
PRKD1, ATM
Protein Ubiquitination Pathway 1.8E-02 USP28, MED20, HSPA1A/HSPA1B, HSPH1
USP19, DNAJA1, HSPA5, HSPA1L, HSPA8
TRAF6, UBE2G1, HSPE1, HSP90AA1, HSPB7
DNAJB6
Reelin Signaling in Neurons 4.2E-02 AKT1, ARHGEF2, PAFAH1B1, VLDLR, ATM
APP
RhoGDI Signaling 2.4E-02 CDH1, PPP1R12C, RHOB, RHOC, GNB2
GNAI1, GNG5, ARHGEF17, ARHGEF2, DLC1
MYL3
Role of Macrophages,
Fibroblasts and Endothelial
Cells in Rheumatoid Arthritis
3.8E-02 SOCS3, TCF4, IL1RL1, TNFRSF1A, CEBPD
IL1R1, CCND1, PLCD1, TRAF6, AKT1, CREB1
MAP2K3, PLCD4, PRKD1, TCF7L2, ATM
Signaling by Rho Family
GTPases
7.6E-03 SEPT8, PPP1R12C, RHOC, SEPT7, GNAI1
ARHGEF17, PLD1, CDH1, RHOB, GNB2
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Canonical Pathways p value Significant genes in the pathway
GNG5, ARHGEF2, PARD3, MYL3, ATM
TR/RXR Activation 1.9E-02 KLF9, AKT1, NXPH2, ACACA, THRA
TBL1XR1, ATM
Type II Diabetes Mellitus
Signaling
3.4E-02 SOCS3, AKT1, TNFRSF1A, MAP3K1, ACSL5
SLC27A3, PRKD1, ATM
B. Additional significant pathways
Activation of IRF by Cytosolic
Pattern Recognition Receptors
1.5E-02 DHX58, IFIH1, TRAF6, ZBP1, IKBKAP, IFIT2
Acute Myeloid Leukemia
Signaling
1.2E-02 TCF4, AKT1, CCNA1, MAP2K3, CCND1
TCF7L2, ATM
Aryl Hydrocarbon Receptor
Signaling
1.9E-03 TGM2, ALDH4A1, CCNA2, ALDH1L1, CCNA1
CCND3, HSP90AA1, HSPB7, DHFR, CCND1
PTGES3, ATM
ATM Signaling 4.4E-02 MDM4, GADD45A, CREB1, BLM, ATM
Biotin-carboxyl Carrier Protein
Assembly
5.9E-03 ACACB, ACACA
Cardiac Hypertrophy Signaling 1.4E-02 MAP3K6, RHOC, MAP3K1, GNAI1, PLCD1
AKT1, RHOB, CREB1, GNB2, GNG5, MAP2K3
PLCD4, MYL3, ATM
Colorectal Cancer Metastasis
Signaling
4.9E-02 TCF4, TNFRSF1A, RHOC, CCND1, MMP24
CDH1, AKT1, MSH2, RHOB, GNB2, GNG5
TCF7L2, ATM
Complement System 2.0E-02 C1R, SERPING1, CD59, CFB
Endometrial Cancer Signaling 2.5E-02 CDH1, AKT1, ERBB2, CCND1, ATM
eNOS Signaling 9.8E-03 HSPA8, CCNA2, AKT1, CCNA1
HSPA1A/HSPA1B, HSP90AA1, HSPA5
NOSTRIN, HSPA1L, ATM
GADD45 Signaling 3.4E-03 GADD45A, CCND3, CCND1, ATM
Germ Cell-Sertoli Cell Junction
Signaling
4.6E-03 PXN, CDH1, AKT1, MAP3K6, RHOB
TNFRSF1A, RHOC, MAP3K1, MTMR2
MAP2K3, TUBA1B, ATM
Glucocorticoid Receptor
Signaling
4.7E-03 HSPA1A/HSPA1B, MAP3K1, HSPA5, CD163
NR3C1, TAF13, TSC22D3, PTGES3, HSPA1L
HSPA8, TRAF6, AKT1, CREB1, FKBP4
HSP90AA1, FKBP5, ATM
HER-2 Signaling in Breast
Cancer
1.1E-02 AKT1, ITGB4, ERBB2, PARD3, CCND1
PRKD1, ATM
Hereditary Breast Cancer
Signaling
3.4E-02 HDAC9, AKT1, MSH2, GADD45A, BLM
CCND1, FANCL, ATM
HIF1α Signaling 4.8E-02 EGLN2, AKT1, EDN1, MAPK4, HSP90AA1
MMP24, ATM
HMGB1 Signaling 3.0E-02 AKT1, RHOB, TNFRSF1A, RHOC, MAP2K3
IL1R1, ATM
Huntington’s Disease Signaling 5.8E-03 HDAC9, HSPA1A/HSPA1B, DNM3, HSPA5
HSPA1L, ZDHHC17, HSPA8, TGM2, DYNC1I2
AKT1, CREB1, GNB2, GNG5, PRKD1, ATM
Hypoxia Signaling in the
Cardiovascular System
1.9E-02 AKT1, EDN1, UBE2G1, CREB1, HSP90AA1
ATM
IL-1 Signaling 3.0E-02 TRAF6, MAP3K1, GNB2, GNAI1, GNG5
MAP2K3, IL1R1
IL-10 Signaling 2.2E-02 TRAF6, SOCS3, IL4R, IL1RL1, MAP2K3, IL1R1
IL-6 Signaling 1.3E-02 TRAF6, SOCS3, AKT1, TNFRSF1A, IL1RL1
HSPB7, MAP2K3, IL1R1, ATM
IL-8 Signaling 3.0E-03 NAPEPLD, RHOC, GNAI1, CCND1, PLD1
TRAF6, CDH1, AKT1, CCND3, RHOB, GNB2
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Canonical Pathways p value Significant genes in the pathway
GNG5, PRKD1, ATM
LPS/IL-1 Mediated Inhibition of
RXR Function
2.7E-02 ALDH4A1, TNFRSF1A, IL1RL1, MAP3K1
IL1R1, FMO5, TRAF6, ALDH1L1, UST, ACSL5
NR5A2, SLC27A3, HS3ST5
LXR/RXR Activation 4.2E-02 SCD, TF, TNFRSF1A, IL1RL1, MYLIP, ACACA
S100A8, IL1R1
Melanoma Signaling 4.5E-02 CDH1, AKT1, CCND1, ATM
P2Y Purigenic Receptor
Signaling Pathway
6.0E-03 PLCD1, AKT1, CREB1, GNB2, GNAI1, P2RY12
GNG5, PLCD4, PRKD1, ATM
p38 MAPK Signaling 3.6E-02 TRAF6, TNFRSF1A, IL1RL1, DUSP10, CREB1
HSPB7, MAP2K3, IL1R1
Phospholipase C Signaling 4.0E-02 HDAC9, NAPEPLD, RHOC, ARHGEF17, PLD1
TGM2, RHOB, CREB1, GNB2, GNG5
ARHGEF2, MYL3, PRKD1
Phospholipases 3.5E-02 PLCD1, NAPEPLD, PLA1A, PLCD4, PLD1
Protein Kinase A Signaling 3.9E-02 TCF4, PXN, PTPRD, MAP3K1, GNAI1, TTN
PDE8A, PLCD1, DUSP10, CREB1, GNB2
GNG5, DUSP7, PLCD4, MYL3, PDE6B
TCF7L2, PRKD1, DUSP16
Role of BRCA1 in DNA
Damage Response
4.4E-02 MSH2, GADD45A, BLM, FANCL, ATM
Role of NFAT in Cardiac
Hypertrophy
3.3E-02 PLCD1, HDAC9, AKT1, MAP3K1, GNB2
GNAI1, GNG5, MAP2K3, PLCD4, PRKD1, ATM
Role of PKR in Interferon
Induction and Antiviral
Response
3.9E-02 TRAF6, AKT1, TNFRSF1A, MAP2K3
Superpathway of D-myo-inositol (1,4,5)-trisphosphate
Metabolism
4.1E-02 INPP1, ITPKC, IMPA2
Thrombin Signaling 8.9E-03 RHOC, GNAI1, PLCD1, AKT1, RHOB, CREB1
GNB2, GNG5, ARHGEF2, PLCD4, MYL3
PRKD1, ATM
Thyroid Cancer Signaling 3.9E-02 CDH1, TCF4, CCND1, TCF7L2
Xanthine and Xanthosine
Salvage
3.2E-02 PNP
γ-linolenate Biosynthesis II
(Animals)
1.6E-02 ACSL5, CYB5R3, SLC27A3
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Table 3
Confirmation by qRT-PCR
Gene
Symbol
RT-PCR
p-value
RT-PCR
Fold
Array
p-value
Array
Fold
FKBP5 2.6E-27 1.84 4.6E-06 2.21
NR3C1 8.6E-03 −1.26 1.8E-05 −1.29
NR4A2 3.9E-02 −1.79 3.5E-04 −1.95
GRM3 1.0E-18 −1.47 2.7E-05 −1.45
Primers used FKBP5, Hs01561010_m1; NR3C1, Hs00353740_m1; NR4A2, Hs00428691_m1; GRM3, Hs00168260_m1; POL2RA,
Hs00172187_m1 used as control to normalize sample-to-sample variation.
Alcohol. Author manuscript; available in PMC 2014 November 01.
